Benitec Biopharma Inc. (BNTC) Form 8-K — May 29, 2026
Benitec Biopharma Inc. appointed David Friedman as a Class III director, effective May 22, 2026, with a term expiring at the 2028 annual meeting. In connection with his appointment, Friedman was granted options to purchase 35,000 shares of common stock, vesting on the earlier of the next annual meeting or the first anniversary of the grant. Megan Boston, the company’s CFO and secretary, resigned from the board on the same date as part of an ongoing governance review.
Key figures
- Options granted
- 35000
Price after filing
Close on the filing date to close N calendar days later (from $11.56). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.